download
FREE KOL List
    • KOL
    • KOLs Community
    • Mouse
    • Mouse Skin
    • Thomas J Slaga
    • Thomas J Slaga

      Thomas J Slaga

      Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX | Department of Pharmacology, The University of Texas ...

       

       

      KOL Resume for Thomas J Slaga

      Year
      2020

      Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX

      2019

      Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

      2018

      Department of Pharmacology, UT Health Science Center San Antonio, San Antonio, Texas

      2017

      Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

      2016

      Department of Pharmacology, The University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, 78229, San Antonio, TX, USA

      2015

      Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.

      2014

      Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA

      2013

      The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

      University of Texas Health Science Center at San Antonio Graduate School of Biomedical Sciences San Antonio Texas

      2012

      Department of Pharmacology, Medical Research Division, Edinburg-Regional Academic Health Center, The University of Texas Health Science Center at San Antonio , Edinburg, TX 78541, USA ,

      2010

      the Departments of Pharmacology,

      University of Texas, San Antonio, Texas

      2009

      Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229

      2008

      AMC Cancer Research Center, Lakewood, Colorado

      2007

      Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

      2004

      Department of Cancer Causation and Prevention, AMC Cancer Research Center, Denver, Colorado 80214 and the University of Colorado Comprehensive Cancer Center, Denver, Colorado 80045

      AMC Cancer Research Center, Denver, CO

      2003

      Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, CO 80214, USA

      2002

      AMC Cancer Research Center, 80214, Lakewood, Colorado, CO, USA

      2001

      AMC Cancer Research Center, 1600 Pierce St., Denver, Colorado

      Center for Cancer Causation and Prevention, American Medical Center Cancer Research Center, Denver, CO 80214;

      2000

      AMC Cancer Research Center, Denver, Colorado, 80214, USA

      1999

      Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, Colorado, 80214

      1998

      M.D. Anderson Cancer Center, Science Park-Research Division, The University of Texas, P.O. Box 389, Smithville, Texas, 78957

      AMC Cancer Research Center, 1600 Pierce Street, Lakewood, CO 80214, USA

      1997

      Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Science Park–Research Division, Smithville, Texas

      1996

      Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park−Research Division, Smithville, Texas 78957, Lankenau Medical Research Center, 100 Lancaster Avenue West of City Line, Wynnewood, Pennsylvania 19096, and Ben May Institute, University of Chicago, Chicago, Illinois 60637

      1995

      M.D. Anderson Cancer Center, Science Park - Research Division, The University of Texas, 78757, Smithville, TX, USA

      1994

      University of Texas, M.D. Anderson Cancer Center, Science Park, Research Division, Smithville, TX, USA

      1993

      University of Texas System Cancer Center, Science Park Research Division, P.O. Box 389, Smithville, TX 78957, USA

      1992

      University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville 78957.

      1991

      Programme of Multistage Carcinogenesis, International Agency for Research on Cancer, Lyon, France.

      Department of Carcinogenesis, Science Park-Research Division, The University of Texas M.D.Anderson Cancer CenterPO Box 389, Smithville, TX 78957, USA

      The University of Texas M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 U.S.A.

      1990

      Department of Carcinogenesis, Science Park‐Research Division, The University of Texas System M.D. Anderson Cancer Center, Smithville, Texas

      1989

      Department of Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas

      1988

      Science Park, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas

      1987

      The University of Texas System Cancer Center, Science Park-Research Division, Smithville, TX 78957 U.S.A.

      1986

      University of Texas System Cancer Center, Science Park-Research Division, Smithville, TX USA

      1985

      The University of Texas System Cancer Center, Science Park-Research DivisionPO Box 389, Smithville, TX 78957

      1984

      Director, Biochemist and Professor of Biochemistry, Ph.D. The University of Texas System Cancer Center Research Division Science Park P.O. Drawer 389 Smithville Texas 78957 U.S.A.

      1983

      Biology Division, Oak Ridge National Laboratory, 37830, Oak Ridge, TN, USA

      University of Texas System Cancer, Center Science Park-Research Division, Smithville, Texas

      1982

      University of Tennessee‐Oak Ridge Graduate School of Biomedical Sciences, Tennessee 37830

      Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, U.S.A.

      1981

      Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee

       

       

      Thomas J Slaga: Influence Statistics

      Sample of concepts for which Thomas J Slaga is among the top experts in the world.
      Concept World rank
      cell 3pc #1
      3hmc interaction #1
      tumorigenesis mouse skin #1
      res survival chloroquine #1
      nmol 712 #1
      twostage promotion #1
      v79 fluoro #1
      2 mezerein #1
      tumor promoter agent #1
      constitutive activation ikk #1
      ru24782 sencar mice #1
      cells abnormal epidermis #1
      tumorpromotion protocol #1
      skin tpa #1
      14fold h2b #1
      expression cx311 #1
      receptor phorbol diesters #1
      antiinflammatory cytokine bap #1
      syndmbadedna adducts method #1
      progression phase model #1
      akt nfkappab pathway #1
      hyperplastic agent #1
      micrococcal nuclease dinucleosomes #1
      viability mouse melanoma #1
      ru24782 #1
      bja cyclopentafused derivative #1
      cholesterol bacteria #1
      repeated tumor experiments #1
      species multistage process #1
      data 506 chemicals #1
      promotion skin #1
      peroxides skin #1
      inhibition mouse epidermis #1
      dmi grmediated transcription #1
      cyclopentafused derivatives benzaanthracene #1
      mnng ethylnitrosourea #1
      ru24782 neoplastic cyclooxygenase #1
      dermis hair follicles #1
      active bacterial cell #1
      mc microsomal metabolizing #1
      coke oven materials #1
      comparative study stocks #1
      pah diolepoxide reacting #1
      mezerein dmba #1
      species differences aspects #1
      3nearest neighbor #1
      5′oh region #1
      mice sencar #1
      micrograms mouse #1
      nfκb component #1

       

      Prominent publications by Thomas J Slaga

      KOL-Index: 16715

      Skin tumors can be effectively induced in mice by the repetitive application of a carcinogen. The relative order of sensitivity to complete carcinogenesis is Sencar > CD-1 > C57BL/6 ≥ BALB/c ≥ ICR/Ha Swiss > C3H. Skin tumors in mice can also be induced by the sequential application of a sub-threshold dose of a carcinogen (initiation phase) followed by repetitive treatment with a weak or noncarcinogenic tumor promoter (promotion phase). The relative order of sensitivity to ...

      Known for Mouse Skin | Multistage Carcinogenesis | Promotion Tpa | C57bl 6 | Dark Basal Keratinocytes
      KOL-Index: 13396

      The mouse skin carcinogenesis protocol is a unique model for understanding the molecular events leading to oncogenic transformation. Mutations in the Ha-ras gene, and the presence of functional cyclin D1 and the EGF receptor, have proven to be important in this system. However, the signal transduction pathways connecting these elements during mouse skin carcinogenesis are poorly understood. This paper studies the relevance of the Akt and ERK pathways in the different stages of chemically ...

      Known for Mouse Skin | Akt Signaling | Neoplastic Genes | Protein Kinase | Mice Mice
      KOL-Index: 13132

      Binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDB) to intact human promyelocytic leukemia cells susceptible (HL-60) or resistant (R-35) to phorbol ester-induced differentiation was characterized. Specific binding of [3H]PDB to both HL-60 and R-35 cells at 37 degrees C reached a maximum within 15-20 min. Maximal specific [3H]PDB binding to HL-60 cells was followed by a decline (down regulation) of radioactivity. This down regulation was temperature dependent, because no loss of ...

      Known for Specific Binding | Leukemia Cells | Phorbol Ester | 37 Degrees | Induced Differentiation
      KOL-Index: 11931

      Rel/NF-kappaB transcription factors are implicated in the control of cell proliferation, apoptosis and transformation. The key to NF-kappaB regulation is the inhibitory IkappaB proteins. During response to diverse stimuli, IkappaBs are rapidly phosphorylated by IkappaB kinases (IKKs), ubiquitinated and undergo degradation. We have investigated the expression and function of NF-kappaB, IkappaB inhibitors and IKKs in normal prostate epithelial cells and prostate carcinoma (PC) cell lines ...

      Known for Constitutive Activation | Prostate Carcinoma | Kappab Transcription | Neoplastic Genes | Androgen Independent
      KOL-Index: 11711

      In this study, the effects of combining ursolic acid + resveratrol, for possible combined inhibitory effects on skin tumor promotion, were evaluated. Ursolic acid, resveratrol, and the combination of ursolic acid + resveratrol were applied topically prior to 12-O-tetracanoylphorbol-13-acetate (TPA) treatment on mouse skin to examine their effect on TPA-induced signaling pathways, epidermal hyperproliferation, skin inflammation, inflammatory gene expression, and skin tumor promotion. The ...

      Known for Ursolic Acid | Skin Tumor | Greater Extent | Individual Compounds | Acetate Tpa
      KOL-Index: 11575

      The effects of nonpromoting and weakly promoting diterpenes on skin tumor promotion by 12-O-tetradecanoylphorbol 13-acetate (TPA) were investigated. When phorbol and phorbol 12,13-diacetate (both nonpromoting) were given simultaneously with TPA after 7,12-dimethylbenz[a]-anthracene (DMBA) initiation in female mice, they had no effect on TPA promotion. However, the nonpromoter 4-O-methyl-TPA and the weak promoter mezerein were found to inhibit TPA promotion in a dose-dependent manner when ...

      Known for Skin Tumor Promotion | Tpa Mezerein | 2 Weeks | Female Mice | Stage Promoter
      KOL-Index: 11468

      The effects of fluocinolone acetonide (FA), retinoic acid (RA), and tosylphenylalanine chloromethyl ketone (TPCK) on two-stage promotion after 7,12-dimethylbenz[a]-anthracene (DMBA) initiation in female Sencar mice were investigated. The two-stage promotion protocol was achieved by twice weekly applications of 2 microgram of 12-O-tetradecanoylphorbol 13-acetate (TPA) for 2 weeks (stage I) followed by twice weekly applications of mezerein for 18 weeks (stage II). Separately stage I and II ...

      Known for Stage Promotion | Potent Inhibitor | Dark Basal Keratinocytes | Fluocinolone Acetonide | Weekly Applications
      KOL-Index: 11196

      Gap junctional intercellular communication (GJIC) of cultured mouse epidermal cells is mediated by a gap junction protein, connexin 43, and is dependent on the calcium concentration in the medium, with higher GJIC in a high-calcium (1.2 mM) medium. In several mouse epidermal cell lines, we found a good correlation between the level of GJIC and that of immunohistochemical staining of E-cadherin, a calcium-dependent cell adhesion molecule, at cell-cell contact areas. The variant cell line ...

      Known for Mouse Epidermal Cells | Intercellular Communication | Connexin 43 | Cadherin Gjic | Gap Junctional
      KOL-Index: 11173

      2-Methoxyestradiol (2-ME), an endogenous metabolite of 17beta-estradiol, is present in human blood and urine. Here we show for the first time that 2-ME significantly inhibited the growth of normal prostate epithelial cells and androgen-dependent LNCaP and androgen-independent DU145 prostate cancer cells. This growth inhibition was accompanied by a twofold increase in the G(2)/M population, with a concomitant decrease in the G(1) population, as shown by cell-cycle analysis. 2-ME treatment ...

      Known for Prostate Cancer | G2 Phase | 2me Treatment | Cell Cycle | Protein P53
      KOL-Index: 10839

      Polyamine levels were evaluated in human HL-60 promyelocytic leukemia cells after treatment with inducers of terminal differentiation. Differentiation in these cells was determined by increases in the percentage of morphologically mature cells and in lysozyme activity. Treatment of the HL-60 cells with phorbol 12-myristate-13-acetate (PMA), phorbol 12,13-didecanoate or other inducers of terminal differentiation such as dimethylsulfoxide and retinoic acid resulted in increased levels of ...

      Known for Polyamine Levels | Leukemia Cells | Phorbol Diesters | Pma Treatment | Putrescine Spermidine
      KOL-Index: 10720

      TUMOUR-PROMOTING agents have been defined by their ability to promote tumour formation on carcinogen-initiated mouse skin. The most potent of these agents are the diesters of phorbol which are the active components of croton oil, the classic promoting substance. Phorbol esters can be chemically modified in a number of positions to form molecules with a wide range of promoter potency1. Such modifications have been useful in determining structure-function relationships2. A good correlation ...

      Known for Phorbol Esters | Dna Synthesis | Decarboxylase Activity | Mouse Epidermal | Cell Cultures

      Key People For Mouse Skin

      Top KOLs in the world
      #1
      Thomas J Slaga
      mouse skin sencar mice tumor promotion
      #2
      Roswell K Boutwell
      ornithine decarboxylase mouse epidermis retinoic acid
      #3
      Stuart H Yuspa
      epidermal cells protein kinase malignant conversion
      #4
      John DiGiovanni
      sencar mice mouse skin tumor promotion
      #5
      Susan M Fischer
      mouse skin epidermal cells sencar mice
      #6
      Hasan Mukhtar
      green tea prostate cancer human skin

      Thomas J Slaga:Expert Impact

      Concepts for whichThomas J Slagahas direct influence:Mouse skin,  Sencar mice,  Tumor promotion,  Skin tumor,  Ursolic acid,  Skin tumors,  Epidermal cells,  Acetic acid.

      Thomas J Slaga:KOL impact

      Concepts related to the work of other authors for whichfor which Thomas J Slaga has influence:Mouse skin,  Protein kinase,  Prostate cancer,  Stem cells,  Tumor promotion,  Cell proliferation,  Gap junctions.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX | Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas | Department of P

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.